Drugs Made In America Acquisition Corp. DMAA
NASDAQ · United States · Finance
$10.89+0.01 (+0.06%)
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
These ratios divide the lines in the statements below by the current price; both inputs of every value are visible on this page. The P/E on the overview comes from the same calculation. P/E and P/S are left blank for loss-making companies or where revenue is not reported. Not investment advice.
| LTM | FY2025 | |
|---|---|---|
| Revenue | $0 | $0 |
| Revenue growth (YoY) | — | — |
| Operating expenses | MakklerPRO | MakklerPRO |
| Operating Income | MakklerPRO | MakklerPRO |
| Operating margin | MakklerPRO | MakklerPRO |
| Net Income | $6.09M | $5.94M |
| Net margin | MakklerPRO | MakklerPRO |
| Diluted EPS | MakklerPRO | MakklerPRO |
| Diluted shares | MakklerPRO | MakklerPRO |
| LTM | FY2025 | |
|---|---|---|
| Cash & equivalents | MakklerPRO | MakklerPRO |
| Total Current Assets | MakklerPRO | MakklerPRO |
| Total Assets | $146.90M | $239.92M |
| Total Current Liabilities | MakklerPRO | MakklerPRO |
| Total Liabilities | MakklerPRO | MakklerPRO |
| Total Equity | MakklerPRO | MakklerPRO |
| LTM | FY2025 | |
|---|---|---|
| Cash from Operations | -$517.15K | -$539.19K |
| Cash from Investing | MakklerPRO | MakklerPRO |
| Cash from Financing | MakklerPRO | MakklerPRO |
Taken from the company's own 10-K and 10-Q filings via the SEC's XBRL data service. The "LTM" column is the last completed fiscal year plus the current year to date, minus the same period a year earlier. Lines a company tags with a non-standard label are left blank rather than filled with an approximation. Not investment advice.